Displaying drugs 1476 - 1500 of 2297 in total
LSZ-102
LSZ-102 is under investigation in clinical trial NCT02734615 (Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers).
Investigational
TOL-101
Investigational
MYR-101
MYR-101 (rAAV-Olig001-ASPA) is a recombinant adeno-associated virus (rAAV) vector-based gene therapy intended to treat Canavan disease. Canavan disease is a fatal childhood genetic disorder characterized by white matter degeneration in the brain. It is caused by a mutation in the aspartoacylase gene (ASPA), which leads to a deficiency of the...
Investigational
SBT-100
SBT-100 is an anti-signal transducer and activator of transcription 3 (STAT3) B VHH13 single-domain antibody (sdAb). It was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma.[L44131,L44136]
Investigational
SUN-101
Investigational
OTL-103
Investigational
DYN-101
DYN-101 is an antisense product candidate designed to reduce the expression of dynamin 2 protein.
Investigational
AVS-100
Investigational
DF-1001
Investigational
FBX-101
FBX-101 is an adeno-associated virus serotype rhesus 10 vector expressing the human galactocerebrosidase (GALC) gene
Investigational
Matched Description: … FBX-101 is an adeno-associated virus serotype rhesus 10 vector expressing the human galactocerebrosidase …
TG-1042
TG-1042 (formerly known as ASN-002) is a recombinant adenovirus carrying the cDNA coding sequence for the human interferon gamma gene.
Investigational
CTR-107
CTR-107 is a synthetic targeted growth factor. It is being investigated for the treatment of familial exudative vitreoretinopathy.
Investigational
LMB-100
LMB-100 is a is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of Pseudomonas exotoxin A with mutations that decrease immunogenicity.
Investigational
Gpi-1046
Experimental
AGI-1096
AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection.
Investigational
XMT-1001
XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity. It is a water-soluble macromolecular conjugate of camptothecin (CPT). In this novel CPT pro-drug, CPT is conjugated with a 70 kDa biodegradable hydrophilic polyacetal, poly (1-hydroxymethylene hydroxylmethylformal). XMT-1001 has demonstrated an improved therapeutic...
Investigational
CTS-1027
CTS-1027 has been used in trials studying the treatment of Hepatitis C and Chronic Hepatitis C Virus Infection.
Experimental
Investigational
CTT-1057
CTT-1057 is under investigation in clinical trial NCT03427476 (CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma).
Investigational
TERN-101
TERN-101 is under investigation in clinical trial NCT04328077 (LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)).
Investigational
ORY-1001
Investigational
PPI-1040
Investigational
NP-10679
Investigational
Displaying drugs 1476 - 1500 of 2297 in total